Chapter 1. Executive Summary
Chapter 2. Scope Of The Study
2.1. Market Definition
2.2. Scope Of The Study
2.2.1. Objectives of Report
Chapter 3. Evolve BI Methodology
Chapter 4. Market Insights and Trends
4.1. Supply/ Value Chain Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat Of New Entrants
4.2.2. Bargaining Power Of Buyers
4.2.3. Bargaining Power Of Suppliers
4.2.4. Threat Of Substitutes
4.2.5. Industry Rivalry
4.3. Impact of COVID-19 on pain management drugs Market
4.3.1. Impact on Market Size
4.3.2. End User Trend, Preferences and Budget Impact
4.3.3. Regulatory Framework/Government Policies
4.3.4. Key Players Strategy to Tackle Negative Impact
4.3.5. Opportunity Window
Chapter 5. Market Dynamics
5.1. Introduction
5.2. DRO Analysis
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
Chapter 6. Global pain management drugs Market, By Drug Class
6.1. Introduction
6.2. NSAIDs
6.3. Anesthetics
6.3. Anticonvulsants
Chapter 7. Global pain management drugs Market, By Indication
7.1. Introduction
7.2. Arthritic Pain
7.3. Neuropathic Pain
7.4. Others
Chapter 8. Global pain management drugs Market, By Region
8.1. Introduction
8.2. North America
8.2.1. Introduction
8.2.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.3. Market Size and Forecast, By Country, 2020 - 2028
8.2.4. Market Size and Forecast, By Drug Class, 2020 - 2028
8.2.5. Market Size and Forecast, By Indication, 2020 – 2026
8.2.6. US
8.2.6.1. Introduction
8.2.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.6.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.2.6.4. Market Size and Forecast, By Indication, 2020 - 2028
8.2.7. Canada
8.2.7.1. Introduction
8.2.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.2.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.2.7.4. Market Size and Forecast, By Indication, 2020 - 2028
8.3. Europe
8.3.1. Introduction
8.3.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.3. Market Size and Forecast, By Country, 2020 - 2028
8.3.4. Market Size and Forecast, By Drug Class, 2020 - 2028
8.3.5. Market Size and Forecast, By Indication, 2020 – 2026
8.3.6. Germany
8.3.6.1. Introduction
8.3.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.6.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.3.6.4. Market Size and Forecast, By Indication, 2020 - 2028
8.3.7. France
8.3.7.1. Introduction
8.3.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.3.7.4. Market Size and Forecast, By Indication, 2020 - 2028
8.3.8. UK
8.3.8.1. Introduction
8.3.8.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.8.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.3.8.4. Market Size and Forecast, By Indication, 2020 - 2028
8.3.9. Italy
8.3.9.1. Introduction
8.3.9.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.9.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.3.9.4. Market Size and Forecast, By Indication, 2020 - 2028
8.3.10. Rest Of Europe
8.3.10.1. Introduction
8.3.10.2. Driving Factors, Opportunity Analyzed and Key Trends
8.3.10.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.3.10.4. Market Size and Forecast, By Indication, 2020 - 2028
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.3. Market Size and Forecast, By Country, 2020 - 2028
8.4.4. Market Size and Forecast, By Drug Class, 2020 - 2028
8.4.5. Market Size and Forecast, By Indication, 2020 - 2028
8.4.6. China
8.4.6.1. Introduction
8.4.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.6.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.4.6.4. Market Size and Forecast, By Indication, 2020 - 2028
8.4.7. India
8.4.7.1. Introduction
8.4.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.4.7.4. Market Size and Forecast, By Indication, 2020 - 2028
8.4.8. Japan
8.4.8.1. Introduction
8.4.8.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.8.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.4.8.4. Market Size and Forecast, By Indication, 2020 - 2028
8.4.9. South Korea
8.4.9.1. Introduction
8.4.9.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.9.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.4.9.4. Market Size and Forecast, By Indication, 2020 - 2028
8.4.10. Rest Of Asia-Pacific
8.4.10.1. Introduction
8.4.10.2. Driving Factors, Opportunity Analyzed and Key Trends
8.4.10.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.4.10.4. Market Size and Forecast, By Indication, 2020 - 2028
8.5. Rest Of The World (RoW)
8.5.1. Introduction
8.5.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.5.4. Market Size and Forecast, By Indication, 2020 - 2028
8.5.5. Market Size and Forecast, By Region, 2020 - 2028
8.5.6. South America
8.5.6.1. Introduction
8.5.6.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.6.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.5.6.4. Market Size and Forecast, By Indication, 2020 - 2028
8.5.7. Middle East and Africa
8.5.7.1. Introduction
8.5.7.2. Driving Factors, Opportunity Analyzed and Key Trends
8.5.7.3. Market Size and Forecast, By Drug Class, 2020 - 2028
8.5.7.4. Market Size and Forecast, By Indication, 2020 - 2028
Chapter 9. Competitive Landscape
9.1. Introduction
9.2. Vendor Share Analysis, 2020/Key Players Positioning, 2020
Chapter 10. Company Profiles
10.1. Novartis AG
10.1.1. Business Overview
10.1.2. Financial Analysis
10.1.3. Product Portfolio
10.1.4. Recent Development and Strategies Adopted
10.1.5. SWOT Analysis
10.2. Eli Lilly & Company
10.2.1. Business Overview
10.2.2. Financial Analysis
10.2.3. Product Portfolio
10.2.4. Recent Development and Strategies Adopted
10.2.5. SWOT Analysis
10.3. Abbott Laboratories
10.3.1. Business Overview
10.3.2. Financial Analysis
10.3.3. Product Portfolio
10.3.4. Recent Development and Strategies Adopted
10.3.5. SWOT Analysis
10.4. Endo Health Solutions, Inc
10.4.1. Business Overview
10.4.2. Financial Analysis
10.4.3. Product Portfolio
10.4.4. Recent Development and Strategies Adopted
10.4.5. SWOT Analysis
10.5. Purdue Pharma L.P
10.5.1. Business Overview
10.5.2. Financial Analysis
10.5.3. Product Portfolio
10.5.4. Recent Development and Strategies Adopted
10.5.5. SWOT Analysis
10.6. Pfizer, Inc.
10.6.1. Business Overview
10.6.2. Financial Analysis
10.6.3. Product Portfolio
10.6.4. Recent Development and Strategies Adopted
10.6.5. SWOT Analysis
10.7. Mylan NV.
10.7.1. Business Overview
10.7.2. Financial Analysis
10.7.3. Product Portfolio
10.7.4. Recent Development and Strategies Adopted
10.7.5. SWOT Analysis
10.8. Merck & Co. Inc
10.8.1. Business Overview
10.8.2. Financial Analysis
10.8.3. Product Portfolio
10.8.4. Recent Development and Strategies Adopted
10.8.5. SWOT Analysis
10.9. Johnson & Johnson
10.9.1. Business Overview
10.9.2. Financial Analysis
10.9.3. Product Portfolio
10.9.4. Recent Development and Strategies Adopted
10.9.5. SWOT Analysis
10.10. GlaxoSmithKline Plc
10.10.1. Business Overview
10.10.2. Financial Analysis
10.10.3. Product Portfolio
10.10.4. Recent Development and Strategies Adopted
10.10.5. SWOT Analysis
Chapter 11. Key Takeaways